title: Brain serotonin 1A receptor binding in bulimia nervosa.
abstract: BACKGROUND
  Selective serotonin reuptake inhibitors (SSRIs) are the first choice for the pharmacologic treatment of bulimia nervosa, but there are no published data on the putative altered serotonin (5-HT) receptor characteristics in patients with bulimia. Experimental studies suggest that the therapeutic antidepressant effect of SSRIs is mediated via 5-HT(1A) receptors. The aim of this study was to measure brain 5-HT(1A) receptor binding among nonmedicated patients with bulimia nervosa.
  
  
  METHODS
  Positron emission tomography (PET) with a selective 5-HT(1A) ligand, [11C]WAY-100635, was performed on eight unmedicated patients with bulimia and 10 healthy comparison subjects.
  
  
  RESULTS
  The binding potential values were greater in patients than in control subjects in all brain regions studied. The most robust differences were observed in the angular gyrus, the medial prefrontal cortex, and the posterior cingulate cortex.
  
  
  CONCLUSIONS
  These results suggest that brain 5-HT(1A) receptor binding is increased in several cortical areas in patients with bulimia nervosa during their state of impulsive binge eating.
authors.affiliation: Department of Psychiatry, University Hospital, University of Helsinki, Helsinki, Finland.
authors.forename: Jari
authors.initials: J
authors.lastname: Tiihonen
authors.forename: Anna
authors.initials: A
authors.lastname: Keski-Rahkonen
authors.forename: Mari
authors.initials: M
authors.lastname: Löppönen
authors.forename: Maria
authors.initials: M
authors.lastname: Muhonen
authors.forename: Jaana
authors.initials: J
authors.lastname: Kajander
authors.forename: Topias
authors.initials: T
authors.lastname: Allonen
authors.forename: Kjell
authors.initials: K
authors.lastname: Någren
authors.forename: Jarmo
authors.initials: J
authors.lastname: Hietala
authors.forename: Aila
authors.initials: A
authors.lastname: Rissanen
mesh_terms: D000328:Adult; D001921:Brain / Q000033:anatomy & histology / Q000378:metabolism*; D002032:Bulimia / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D007839:Functional Laterality; D006801:Humans; D010879:Piperazines / Q000493:pharmacokinetics; D011485:Protein Binding; D011725:Pyridines / Q000493:pharmacokinetics; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000493:pharmacokinetics; D018709:Statistics, Nonparametric; D014055:Tomography, Emission-Computed / Q000379:methods
chemical_list: D010879:Piperazines; D011725:Pyridines; D012702:Serotonin Antagonists; D044282:Receptor, Serotonin, 5-HT1A; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide